Analysis and Commentary STEVEN GROSSMAN 11/3/23 Analysis and Commentary STEVEN GROSSMAN 11/3/23 Level-Funding in FY 24: A Substantial Risk to FDA Priorities Read More Analysis and Commentary STEVEN GROSSMAN 10/27/23 Analysis and Commentary STEVEN GROSSMAN 10/27/23 Concrete Progress; Still A Long Way from Settling FDA’s FY 24 Funding Read More Analysis and Commentary STEVEN GROSSMAN 10/13/23 Analysis and Commentary STEVEN GROSSMAN 10/13/23 FY 24 Appropriations: House Options Limited Regardless of Who Becomes Speaker Read More Analysis and Commentary STEVEN GROSSMAN 10/6/23 Analysis and Commentary STEVEN GROSSMAN 10/6/23 Lots to Learn from a Near-Shutdown Experience Read More Analysis and Commentary STEVEN GROSSMAN 9/29/23 Analysis and Commentary STEVEN GROSSMAN 9/29/23 More Q&A As the Shutdown Becomes Inevitable Read More Analysis and Commentary STEVEN GROSSMAN 9/22/23 Analysis and Commentary STEVEN GROSSMAN 9/22/23 Shutdown Becomes a Near-Certainty: Your Questions Answered Read More Analysis and Commentary STEVEN GROSSMAN 9/15/23 Analysis and Commentary STEVEN GROSSMAN 9/15/23 Q&A: Shutdowns at FDA Are Complicated Part 2 Read More Analysis and Commentary STEVEN GROSSMAN 9/8/23 Analysis and Commentary STEVEN GROSSMAN 9/8/23 Q&A: Shutdowns at FDA Are Complicated Read More Analysis and Commentary STEVEN GROSSMAN 9/1/23 Analysis and Commentary STEVEN GROSSMAN 9/1/23 Product Shortages’ Prominent Place on FDA’s Agenda Read More Analysis and Commentary STEVEN GROSSMAN 8/25/23 Analysis and Commentary STEVEN GROSSMAN 8/25/23 Commissioner Califf Talks About AI Read More Analysis and Commentary STEVEN GROSSMAN 8/4/23 Analysis and Commentary STEVEN GROSSMAN 8/4/23 FDA Funding Judged in Absolute and Relative Terms Read More Analysis and Commentary STEVEN GROSSMAN 7/28/23 Analysis and Commentary STEVEN GROSSMAN 7/28/23 FDA, Appropriations, and Chaos: The Risk of a Perfect Storm Read More Analysis and Commentary STEVEN GROSSMAN 7/21/23 Analysis and Commentary STEVEN GROSSMAN 7/21/23 “FDA Brings Good Things to Life” Read More Analysis and Commentary STEVEN GROSSMAN 7/14/23 Analysis and Commentary STEVEN GROSSMAN 7/14/23 FDA and the Threat of Sequester Read More Analysis and Commentary STEVEN GROSSMAN 6/30/23 Analysis and Commentary STEVEN GROSSMAN 6/30/23 The State of FY 24 Appropriations: Four Answers to Not-So-Easy Questions Read More Analysis and Commentary STEVEN GROSSMAN 6/23/23 Analysis and Commentary STEVEN GROSSMAN 6/23/23 Q&A on Senate Appropriations Markup Read More Analysis and Commentary STEVEN GROSSMAN 6/16/23 Analysis and Commentary STEVEN GROSSMAN 6/16/23 Q&A on House Appropriations Markup Read More Analysis and Commentary STEVEN GROSSMAN 6/9/23 Analysis and Commentary STEVEN GROSSMAN 6/9/23 Budget Deal Sets Parameters But Many Unknowns Read More Analysis and Commentary STEVEN GROSSMAN 6/2/23 Analysis and Commentary STEVEN GROSSMAN 6/2/23 The Budget Deal - First Impressions from an FDA Perspective Read More Analysis and Commentary STEVEN GROSSMAN 5/19/23 Analysis and Commentary STEVEN GROSSMAN 5/19/23 The Macro- and Micro- Budget Processes and Their Impact on FDA Resources Read More Newer Posts Older Posts
Analysis and Commentary STEVEN GROSSMAN 11/3/23 Analysis and Commentary STEVEN GROSSMAN 11/3/23 Level-Funding in FY 24: A Substantial Risk to FDA Priorities Read More
Analysis and Commentary STEVEN GROSSMAN 10/27/23 Analysis and Commentary STEVEN GROSSMAN 10/27/23 Concrete Progress; Still A Long Way from Settling FDA’s FY 24 Funding Read More
Analysis and Commentary STEVEN GROSSMAN 10/13/23 Analysis and Commentary STEVEN GROSSMAN 10/13/23 FY 24 Appropriations: House Options Limited Regardless of Who Becomes Speaker Read More
Analysis and Commentary STEVEN GROSSMAN 10/6/23 Analysis and Commentary STEVEN GROSSMAN 10/6/23 Lots to Learn from a Near-Shutdown Experience Read More
Analysis and Commentary STEVEN GROSSMAN 9/29/23 Analysis and Commentary STEVEN GROSSMAN 9/29/23 More Q&A As the Shutdown Becomes Inevitable Read More
Analysis and Commentary STEVEN GROSSMAN 9/22/23 Analysis and Commentary STEVEN GROSSMAN 9/22/23 Shutdown Becomes a Near-Certainty: Your Questions Answered Read More
Analysis and Commentary STEVEN GROSSMAN 9/15/23 Analysis and Commentary STEVEN GROSSMAN 9/15/23 Q&A: Shutdowns at FDA Are Complicated Part 2 Read More
Analysis and Commentary STEVEN GROSSMAN 9/8/23 Analysis and Commentary STEVEN GROSSMAN 9/8/23 Q&A: Shutdowns at FDA Are Complicated Read More
Analysis and Commentary STEVEN GROSSMAN 9/1/23 Analysis and Commentary STEVEN GROSSMAN 9/1/23 Product Shortages’ Prominent Place on FDA’s Agenda Read More
Analysis and Commentary STEVEN GROSSMAN 8/25/23 Analysis and Commentary STEVEN GROSSMAN 8/25/23 Commissioner Califf Talks About AI Read More
Analysis and Commentary STEVEN GROSSMAN 8/4/23 Analysis and Commentary STEVEN GROSSMAN 8/4/23 FDA Funding Judged in Absolute and Relative Terms Read More
Analysis and Commentary STEVEN GROSSMAN 7/28/23 Analysis and Commentary STEVEN GROSSMAN 7/28/23 FDA, Appropriations, and Chaos: The Risk of a Perfect Storm Read More
Analysis and Commentary STEVEN GROSSMAN 7/21/23 Analysis and Commentary STEVEN GROSSMAN 7/21/23 “FDA Brings Good Things to Life” Read More
Analysis and Commentary STEVEN GROSSMAN 7/14/23 Analysis and Commentary STEVEN GROSSMAN 7/14/23 FDA and the Threat of Sequester Read More
Analysis and Commentary STEVEN GROSSMAN 6/30/23 Analysis and Commentary STEVEN GROSSMAN 6/30/23 The State of FY 24 Appropriations: Four Answers to Not-So-Easy Questions Read More
Analysis and Commentary STEVEN GROSSMAN 6/23/23 Analysis and Commentary STEVEN GROSSMAN 6/23/23 Q&A on Senate Appropriations Markup Read More
Analysis and Commentary STEVEN GROSSMAN 6/16/23 Analysis and Commentary STEVEN GROSSMAN 6/16/23 Q&A on House Appropriations Markup Read More
Analysis and Commentary STEVEN GROSSMAN 6/9/23 Analysis and Commentary STEVEN GROSSMAN 6/9/23 Budget Deal Sets Parameters But Many Unknowns Read More
Analysis and Commentary STEVEN GROSSMAN 6/2/23 Analysis and Commentary STEVEN GROSSMAN 6/2/23 The Budget Deal - First Impressions from an FDA Perspective Read More
Analysis and Commentary STEVEN GROSSMAN 5/19/23 Analysis and Commentary STEVEN GROSSMAN 5/19/23 The Macro- and Micro- Budget Processes and Their Impact on FDA Resources Read More
